» Articles » PMID: 28424670

Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Species and Other Enteric Microbes

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2017 Apr 21
PMID 28424670
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

is a bacterium that is associated with inflammatory bowel disease (IBD). Immunosuppressive drugs including azathioprine (AZA) and mercaptopurine (MP), and anti-inflammatory drug such as 5-aminosalicylic acid (5-ASA) are commonly used to treat patients with IBD. This study aimed to examine the effects of AZA, MP, and 5-ASA on the growth of IBD-associated bacterial species and to identify bacterial enzymes involved in immunosuppressive drug metabolism. A total of 15 bacterial strains of five species including 11 strains, , and were examined. The impact of AZA, MP, and 5-ASA on the growth of these bacterial species was examined quantitatively using a plate counting method. The presence of enzymes involved in AZA and MP metabolism in these bacterial species was identified using bioinformatics tools. AZA and MP significantly inhibited the growth of all 11 strains. strains were more sensitive to AZA than MP. 5-ASA showed inhibitory effects to some strains, while it promoted the growth of other strains. AZA and MP also significantly inhibited the growth of and . The growth of was significantly inhibited by 200 μg/ml of AZA as well as 100 and 200 μg/ml of 5-ASA. Bacterial enzymes related to AZA and MP metabolism were found, which varied in different bacterial species. In conclusion, AZA and MP have inhibitory effects to IBD-associated and other enteric microbes, suggesting an additional therapeutic mechanism of these drugs in the treatment of IBD. The strain dependent differential impact of 5-ASA on the growth of may also have clinical implication given that in some cases 5-ASA medications were found to cause exacerbations of colitis.

Citing Articles

Precision medicine in inflammatory bowel disease.

Zeng Z, Jiang M, Li X, Yuan J, Zhang H Precis Clin Med. 2024; 6(4):pbad033.

PMID: 38638127 PMC: 11025389. DOI: 10.1093/pcmedi/pbad033.


Synthesis and Bioactive Properties of the Novel Coloured Compound Obtained via the Laccase-Mediated Transformation of 5-Aminosalicylic Acid.

Polak J, Graz M, Szalapata K, Kapral-Piotrowska J, Wlizlo K, Polak M Molecules. 2024; 29(6).

PMID: 38542946 PMC: 10975993. DOI: 10.3390/molecules29061310.


Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy.

Zhao Y, He R, Zang J, Yin W, Su R, Xiong W J Nanobiotechnology. 2023; 21(1):444.

PMID: 37996883 PMC: 10668504. DOI: 10.1186/s12951-023-02227-0.


Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.

OReilly C, Mills S, Rea M, Lavelle A, Ghosh S, Hill C Microbiome Res Rep. 2023; 2:35.

PMID: 37849974 PMC: 7615213. DOI: 10.20517/mrr.2023.41.


Manipulating Microbiota in Inflammatory Bowel Disease Treatment: Clinical and Natural Product Interventions Explored.

Zhu M, Song Y, Xu Y, Xu H Int J Mol Sci. 2023; 24(13).

PMID: 37446182 PMC: 10342055. DOI: 10.3390/ijms241311004.


References
1.
Zhang L, Peng X, Damu G, Geng R, Zhou C . Comprehensive review in current developments of imidazole-based medicinal chemistry. Med Res Rev. 2013; 34(2):340-437. DOI: 10.1002/med.21290. View

2.
Sieswerda L, Bannatyne R . Mapping the effects of genetic susceptibility and Mycobacterium avium subsp. paratuberculosis infection on Crohn's disease: strong but independent. J Clin Microbiol. 2006; 44(3):1204-5. PMC: 1393152. DOI: 10.1128/JCM.44.3.1204-1205.2006. View

3.
Sahasranaman S, Howard D, Roy S . Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008; 64(8):753-67. DOI: 10.1007/s00228-008-0478-6. View

4.
Mahendran V, Tan Y, Riordan S, Grimm M, Day A, Lemberg D . The prevalence and polymorphisms of zonula occluden toxin gene in multiple Campylobacter concisus strains isolated from saliva of patients with inflammatory bowel disease and controls. PLoS One. 2013; 8(9):e75525. PMC: 3781098. DOI: 10.1371/journal.pone.0075525. View

5.
Elitsur Y, Freedland C, Luk G . Inhibition of DNA synthesis in human peripheral and lamina propria lymphocytes by 5-aminosalicylic acid and hydrocortisone. Reg Immunol. 1990; 3(1):56-61. View